Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004

Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004

In-Hospital Initiation of Secondary Stroke Prevention Therapies Yields High Rates of Adherence at Follow-up
Stroke 35:2879-2883, Ovbiagele,B.,et al, 2004

Statins in Stroke Prevention and Carotid Artherosclerosis, Systematic Review and Up-to-Date Meta-Analysis
Stroke 35:2902-2909, Amarenco,P.,et al, 2004

Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004

Post-Streptococcal Autoimmune Disorders of the Central Nervous System
Curr Opin Neurol 16:359-365, Snider,L. &Swedo,S., 2003

Trends in Community Knowledge of the Warning Signs and Risk Factors for Stroke
JAMA 289:343-346, Schneider,A.T.,et al, 2003

Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs
Stroke 34:379-386, Bak,S.,et al, 2003

Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Further Vascular Events After Transient Ischemic Attack or Minor Stroke of Presumed Arterial Origin
Stroke 34:234-235, Algra,A.,et al, 2003

Platelet Function Under Aspirin, Clopidogrel, and Both After Ischemic Stroke
Stroke 34:849-855, Grau,A.J.,et al, 2003

Secondary Prevention of Stroke in Italy
Stroke 34:1010-1014, Filippi,A.,et al, 2003

Palinopsia
Lancet 361:1098, Smith,P.E.M.,et al, 2003

Influenza Vaccination and Reduction in Hospitalizations for Cardiac Disease and Stroke Among the Elderly
NEJM 348:1322-1332, Nichol,K.L.,et al, 2003

Blood Pressure-Lowering for Secondary Prevention of Stroke: ACE Inhibition Is Not the Key
Stroke 34:1334-1335,1335, Bath,P., 2003

Blood Pressure--Lowering for Secondary Prevention of Stroke: ACE Inhibition Is the Key
Stroke 34:1333-1334,1334, Anderson,C., 2003

Should Asymptomatic Patients with Hereditary Haemorrhagic Telangiectasia (HHT) be Screened for Cerebral Vascular Malformations? Data from 22 061 years of HHT Patient Life
JNNP 74:743-748, Easey,A.J.,et al, 2003

Oral Anticoagulation in Patients After Cerebral Ischemia of Arterial Origin and Risk of Intracranial Hemorrhage
Stroke 34:e45, ESPRIT, 2003

Major Risk Factors for Aneurysmal Subarrachnoid Hemorrhage in the Young are Modifiable
Stroke 34:1375-1381, Broderick,J.P.,et al, 2003

Cerebral Ischemic Events After Diagnosis of Mitral Valve Prolapse
Stroke 34:1339-1345, Avierinos,J.,et al, 2003

Abdominal Obesity and Risk of Ischemic Stroke
Stroke 34:1586-1592, Suk,S.,et al, 2003

Mental Retardation
Neurol 61:156-157, Patterson,M.C. &Zoghbi,H.Y., 2003

A Risk Score for Predicting Stroke or Death in Individuals with New-Onset Atrial Fibrillation in the Community
JAMA 290:1049-1056,1093, Wang,T.J.,et al, 2003

Stroke Prevention in Atrial Fibrillation
JAMA 290:1093-1095, Waldo,A.L., 2003

Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
NEJM 349:1019-1026, Hylek,E.M.,et al, 2003

Should I Start All My Ischaemic Stroke and TIA Patients on a Statin, an ACE Inhibitor, a Diuretic, and Aspirin Today?
JNNP 74:1461-1464, Sandercock,P.A.G., 2003

Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events
Stroke 34:2741-2749, Rashid,P.,et al, 2003

Dietary Antioxidants and the Risk of Ischemic Stroke
Neurol 61:1273-1275, Voko,Z.,et al, 2003

Mechanisms of Stroke Protection by Physical Activity
Ann Neurol 54:582-590, Endres,M.,et al, 2003

Stroke
Lancet 362:1211-1224, Warlow,C.,et al, 2003

Physical Activity and Stroke Risk
Stroke 34:2475-2482, Lee,C.D.,et al, 2003

A 50-Year-Old Woman With Atrial Fibrillation
JAMA 290:2182-2189, Singer,D.E., 2003

Hyperhomocysteinemia as an Independent Risk Factor for Silent Brain Infarction
Neurol 61:1595-1599, Kim,N.K.,et al, 2003

Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003

10 Most Commonly Asked Questions About Which Antiplatelet Agent to Prescribe
The Neurologist 9:318-322, Adams,H.P. Jr., 2003

The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis
Neurol 61:1332-1338, Goodin,D.S.,et al, 2003

Genetic, Clinical, and Radiographic Delineation of Hallervorden-Spatz Syndrome
NEJM 348:33-40, Hayflick,S.J.,et al, 2003

Determination of Lipid Profiles and Use of Statins in Patients With Ischemic Stroke or Transient Ischemic Attack
Stroke 34:105-110, Lalouschek,W.,et al, 2003

Mitoxantrone in Progressive Multiple Sclerosis: A Placebo-Controlled, Double-Blind, Randomised, Multicentre Trial
Lancet 360:2018-2025, Hartung,H.,et al, 2002

Prognostic Importance of Leukoaraiosis in Patients with Symptomatic Internal Carotid Artery Stenosis
Stroke 33:1651-1655, Streifler,J.Y.,et al, 2002

Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial
Stroke 33:1723-1726, Hankey,G.J., 2002

Aspirin Should be First-Line Antiplatelet Therapy in the Secondary Prevention of Stroke
Stroke 33:2137-2139, Warlow,C., 2002

Serum Potassium Level and Dietary Potassium Intake as Risk Factors for Stroke
Neurol 59:314-320,302, Green,D.M.,et al, 2002

Clinical Features and ATTCT Repeat Expansion in Spinocerebellar Ataxia Type 10
Arch Neurol 59:1285-1290, Grewal,R.P.,et al, 2002

Reversible Chorea and Focal Dystonia in Vitamin B12 Deficiency
NEJM 347:295, Pacchetti,C.,et al, 2002

Blood Pressure Control in Stroke Patients
Neurol 59:23-25, Messerli,F.H.,et al, 2002

Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke
Neurol 59:13-22, Coull,B.M.,et al, 2002

Transoesophageal Echocardiography in Selecting Patients for Anticoagulation After Ischaemic Stroke or Transient Ischaemic Attack
JNNP 73:29-33, Strandberg,M.,et al, 2002

Angioplasty and Stenting for Stroke Prevention, Good Questions That Need Answers
Neurol 59:664-668, Chaturvedi,S.&Fessler,R., 2002

Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002

Assessment of Normal-Appearing White and Gray Matter in Patients with Primary Progressive Multiple Sclerosis
Arch Neurol 59:1406-1412, Rovaris,M.,et al, 2002